<h3>享受 TipRanks Premium 50% 折扣，放心投資</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
<p>CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) 發佈了最新動態。</p>
<p>CARsgen Therapeutics 已將現有股票回購計劃的期限延長至下次年度股東大會結束，之前已根據 2025 年回購授權回購了 7,627,000 股。此次回購由非 IPO 來源（如業務發展和利息收入）資助，董事會將此舉視為公司股價低估其長期增長前景的信號，並作為提升股東價值的措施。此外，主要股東 YIJIE Biotech Holding Limited 及其一致行動人已將其持股比例提高至約 38.2%（不包括庫藏股），董事會將此發展解讀為市場對 CARsgen 長期投資吸引力的進一步信心，儘管未來的回購仍然是自主決定，並受市場條件的影響。</p>
<p>關於 (HK:2171) 股票的最新分析師評級為賣出，目標價為 HK$14.92。要查看 CARsgen Therapeutics Holdings Ltd. 股票的完整分析師預測列表，請參見 HK:2171 股票預測頁面。</p>
<p><strong>關於 CARsgen Therapeutics Holdings Ltd. 的更多信息</strong></p>
<p>CARsgen Therapeutics Holdings Limited 是一家生物技術公司，專注於開發創新的細胞療法，特別是針對癌症的 CAR-T 治療。該公司在香港證券交易所上市，通過子公司和關聯實體運營，針對國內和全球腫瘤市場提供先進的免疫療法產品。</p>
<p><strong>平均交易量：</strong> 1,968,220</p>
<p><strong>技術情緒信號：</strong> 賣出</p>
<p><strong>當前市值：</strong> HK$8.6B</p>
<p>在 TipRanks 的股票分析頁面上查找關於 2171 股票的詳細分析。</p>

科濟藥業-B

<p>CARsgen Therapeutics Holdings Ltd. 已將其股票回購計劃延長至下次年度股東大會，已回購 7,627,000 股。此次回購資金來源於非首次公開募股的渠道，旨在提升股東價值，表明公司認為其股票被低估。此外，YIJIE Biotech Holding Limited 已將其持股比例增加至 38.2%，反映出市場對 CARsgen 長期前景的信心。最新的分析師評級為 “賣出”，目標價格為 14.92 港元</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投資</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
</div><p>CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has issued an update.</p>
<div class="lb-trans"><p>CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) 發佈了最新動態。</p>
</div><p>CARsgen Therapeutics has extended the term of its existing share repurchase plan to run until the conclusion of its next annual general meeting, after having already bought back 7,627,000 shares under its 2025 repurchase mandate. Funded by non-IPO sources such as business development and interest income, the move is framed by the board as a signal that the company’s share price undervalues its long-term growth prospects and as a measure to enhance shareholder value. Separately, substantial shareholder YIJIE Biotech Holding Limited and its concert parties have increased their stake to about 38.2% of issued shares (excluding treasury shares), a development the board interprets as further market confidence in CARsgen’s long-term investment appeal, albeit with the caveat that future buybacks remain discretionary and subject to market conditions.</p>
<div class="lb-trans"><p>CARsgen Therapeutics 已將現有股票回購計劃的期限延長至下次年度股東大會結束，之前已根據 2025 年回購授權回購了 7,627,000 股。此次回購由非 IPO 來源（如業務發展和利息收入）資助，董事會將此舉視為公司股價低估其長期增長前景的信號，並作為提升股東價值的措施。此外，主要股東 YIJIE Biotech Holding Limited 及其一致行動人已將其持股比例提高至約 38.2%（不包括庫藏股），董事會將此發展解讀為市場對 CARsgen 長期投資吸引力的進一步信心，儘管未來的回購仍然是自主決定，並受市場條件的影響。</p>
</div><p>The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.</p>
<div class="lb-trans"><p>關於 (HK:2171) 股票的最新分析師評級為賣出，目標價為 HK$14.92。要查看 CARsgen Therapeutics Holdings Ltd. 股票的完整分析師預測列表，請參見 HK:2171 股票預測頁面。</p>
</div><p><strong>More about CARsgen Therapeutics Holdings Ltd.</strong></p>
<div class="lb-trans"><p><strong>關於 CARsgen Therapeutics Holdings Ltd. 的更多信息</strong></p>
</div><p>CARsgen Therapeutics Holdings Limited is a biotechnology company focused on developing innovative cell therapies, particularly CAR-T treatments, for cancer. Listed on the Hong Kong Stock Exchange, the group operates through subsidiaries and affiliated entities, targeting both domestic and global oncology markets with advanced immunotherapy products.</p>
<div class="lb-trans"><p>CARsgen Therapeutics Holdings Limited 是一家生物技術公司，專注於開發創新的細胞療法，特別是針對癌症的 CAR-T 治療。該公司在香港證券交易所上市，通過子公司和關聯實體運營，針對國內和全球腫瘤市場提供先進的免疫療法產品。</p>
</div><p><strong>Average Trading Volume:</strong> 1,968,220</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 1,968,220</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技術情緒信號：</strong> 賣出</p>
</div><p><strong>Current Market Cap:</strong> HK$8.6B</p>
<div class="lb-trans"><p><strong>當前市值：</strong> HK$8.6B</p>
</div><p>Find detailed analytics on 2171 stock on TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>在 TipRanks 的股票分析頁面上查找關於 2171 股票的詳細分析。</p>
</div>

科濟藥業-B 延長了股票回購計劃，同時主要股東增加了持股比例